Showing 10 posts of 10 posts found.

FDA advisory committee votes in support of favourable benefit-risk profile for ARS Pharmaceuticals’ allergic reaction treatment

May 12, 2023
Research and Development ARS Pharmaceuticals, Allergic Disorders, FDA, allergy

US-based biopharmaceutical company ARS Pharmaceuticals has announced that the US Food and Drug Administration (FDA)’s Pulmonary-Allergy Drug Advisory Committee (PADAC) …


Camallergy awarded £1.1m government funding for peanut allergy immunotherapy

March 9, 2021
Manufacturing and Production Camallergy, UK, allergy

Camallergy, a biopharmaceutical company dedicated to providing innovative, patient-centric treatments for life-threatening food allergies, today announced it has been awarded …


European Commission approves EU’s first peanut allergy treatment

December 21, 2020
Sales and Marketing Aimmune, European Commission, allergy

Aimmune Therapeutics today announced that the European Commission (EC) has approved PALFORZIA as the EU’s first-ever treatment of peanut allergy. …


The American Academy of Allergy, Asthma and Immunology calls off its 2020 Annual Meeting due to coronavirus concerns

March 10, 2020
Medical Communications, Research and Development Big Pharma, allergy, america, asthma, immunology

The American Academy of Allergy, Asthma and Immunology (AAAAI) has called off its 2020 Annual Meeting that was schedule to …

FDA knocks back Glenmark’s allergic rhinitis therapy Ryaltris

June 25, 2019
Manufacturing and Production, Sales and Marketing FDA, Glenmark, Ryaltris, US, allergy, pharma

Stocks in Indian pharmaceutical firm Glenmark were sent plummeting to a six-year low after it was confirmed that the FDA …


FDA approves Beximco’s generic version of MSD’s allergy drug Periactin

April 25, 2019
Sales and Marketing FDA, MSD, Periactin, allergy, generics, pharma

Bangladesh-based Beximco Pharma is celebrating following the decision from the FDA to approve its generic version of MSD’s antihistamine therapy …


Aimmune’s peanut allergy therapy closes in on approval with promising Phase 3 data

March 26, 2019
Manufacturing and Production, Research and Development AR101, Aimmune, allergy, pharma

Aimmune Therapeutics is gearing up for regulatory review of its investigational food allergy therapy AR101 following the release of new …


Allergy Therapeutics’ adjuvanted birch allergoid drug shocks with Phase 3 failure

March 18, 2019
Research and Development, Sales and Marketing allergy, allergy therapeutics, pharma, trial failure

UK-based biotech firm Allergy Therapeutics has been left disappointed after it became evident that its adjuvanted birch allergoid product failed …


FDA accepts biologics license application for MSD’s allergy immunotherapy drug

April 13, 2016
Research and Development, Sales and Marketing MSD, Merck, allergy, dust mite, house, immunotherapy, mk-8237

MSD (NYSE: MRK) has announced that the US Food and Drug Administration has accepted for review the biologics license application …

Lane Earl Cox wins allergy blood test account

April 16, 2010
Medical Communications LEC, Phadia, allergy

Healthcare advertising agency Lane Earl & Cox has won the account to promote an allergy blood test product from diagnostics …

Latest content